Analyzing shopping habits to improve early cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Cancer Loyalty Card Study 2 (CLOCS-2) aims to investigate whether changes in purchasing behaviors, as recorded by loyalty cards from high street retailers, can serve as early indicators of cancer diagnosis. This observational study will recruit at least 750 recently diagnosed cancer patients and 750 control participants without cancer, collecting up to six years of prior purchase data. Participants must be 18 years or older and hold a loyalty card from participating retailers. The study will utilize secure data management practices to ensure participant confidentiality.

Why it matters

Who can join: the full rules

Inclusion Criteria (ALL):

* Individuals aged \>18 years of age
* Individuals must be residing in the United Kingdom at the time of giving informed consent
* Individuals must be registered with an NHS GP Practice
* Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).
* Individuals must be a primary registered cardholder\* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team
* Tesco Clubcard
* Boots Advantage Card
* Provision of written informed consent
* Willing and able to comply with all required study activities

  * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.

Exclusion Criteria (ALL):

* Individuals under the age of 18 years
* Non-UK residents, at the time of giving informed consent
* Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card
* Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and/or where the primary registered cardholder does not make purchases for or on behalf of the individual

Exclusion Criteria (CASES):

• Individuals will not be able to join as a case if:

* they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).
* they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).

Exclusion Criteria (Controls):

• Individuals will not be able to join as a control (Group 2) if:

o they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).

Where it's running

• Imperial College Healthcare NHS Trust
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Dr James Flanagan — Imperial College London
• Study coordinator: Yuscah Pondeca
• Email: yuscah.pondeca16@imperial.ac.uk
• Phone: 02075942127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.